Body proportions during 6 years of GH treatment in children with short stature born small for gestational age participating in a randomised, double‐blind, dose–response trial*

Objectives: To describe population reference values for shoes size, and to identify possible disproportional foot growth during GH therapy. Materials and methods: Construction of percentile chart based on 3,651 controls (male: 1,838; female: 1,813). The GH treated group included 13 children with idiopathic short stature (ISS) and 50 children with normal height, but with height prediction below their target height; male: 26 and female: 37 mean ± SD age 13.3 ± 1.9 and 12.9 ± 1.5 years, respectively. GH (0.05 mg/kg/day) was used for 3.2 ± 1.6 years, ranging from 1.0-10.3 years. Height expressed as SDS, target height (TH) SDS, self-reported shoes size and target shoes size (TSS) SDS were recorded. Results: Reference values were established showed as a foot SDS calculator available online at www.clinicalcaselearning.com/v2. Definitive shoes size was attained in controls at mean age of 13y in girls and 14y in boys (average values 37 and 40, respectively). In the study group, shoes size was -0.15 ± 0.9 and -0.02 ± 1.3 SDS, with target feet of 0.08 ± 0.8 and -0.27 ± 0.7 SDS in males and females, respectively. There was a significant positive correlation between shoes size and familial TSS, between shoes size and height and between TSS and TH. There was no correlation between duration of GH treatment and shoes size. Our data suggest that during long-term treatment with GH, patients maintain proportional growth in shoes size and height, and the expected correlation with the familial target. Conclusions: We conclude that there is no excessive increase in the size of foot as estimated by the size of shoes in individuals under long term GH therapy. Arch Endocrinol Metab. 2015;59(5):414-21

show abstract

“…SGA infants have small hands and feet as compared to controls, presenting partial recovery during GH therapy (13).…”

Section: Discussionmentioning

confidence: 99%

Reported shoes size during GH therapy: is foot overgrowth a myth or reality?

Lago

Coutinho

Kochi

et al. 2015

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

show abstract

“…The initial age, the dose used, and the height deficit related to the parents height at the beginning of the treatment are predictor factors of the growth response [20–24]. These results were independent of the GH status [23, 25–30].…”

Section: Introductionmentioning

confidence: 99%

IGF-I and IGF Binding Protein-3 Generation Tests and Response to Growth Hormone in Children with Silver-Russell Syndrome

Beserra

Ribeiro

Collett‐Solberg

et al. 2010

International Journal of Pediatric Endocrinology

View full text Add to dashboard Cite

Objectives. To evaluate, in children with Silver-Russell Syndrome, the response to the IGF-I and IGFBP-3 generation test and compare results to the growth response after 6 months of rhGH. Methods. Eight children (6 males), with a mean age of 5.71 ± 2.48 years and height SDS of −3.88 ± 1.28 received rhGH for 6 months. IGF-I and IGFBP-3 were analyzed before and after 4 doses of rhGH. Results. The mean growth velocity (GV) before treatment was 5.28 ± 1.9 cm/year. GV increased after rhGH in five children to a mean GV of 10.3 ± 3.64 cm/year. Six children had normal basal IGF-I levels and two low levels. After 4 doses of rhGH, the IGF-I levels were normal in seven. There was no correlation between the growth response and the IGF-I generation test. Conclusions. Children with SRS have normal IGF-I generation test. There is no correlation between the generation test and the growth velocity after 6 months of rhGH.

show abstract

“…Data was evaluated of 201 SGA children with persistent short stature who were participating in prospective cohort trials evaluating the effect of GH treatment [4,5,6,7,8,9]. SGA was defined as a birth length ≤–2.00 SDS [10].…”

Section: Methodsmentioning

confidence: 99%

Subclassification of Small for Gestational Age Children with Persistent Short Stature: Growth Patterns and Response to GH Treatment

et al. 2007

View full text Add to dashboard Cite

Aim: We determined whether subclassification of short small for gestational age (SGA) children according to birth anthropometrics could delineate different patterns in gestation, delivery, postnatal growth, response to growth hormone (GH) treatment and parental height. Methods: 201 short SGA children were divided into three groups, SGA_L, SGA_L+W and SGA_L+W+HC, according to birth length (L), weight (W) and head circumference (HC) ≤–2.00 standard deviation score (SDS). Results: SGA_L+W+HC children were born after the shortest gestational age and more often by caesarean section than SGA_L children (36.3 vs. 38.1 weeks, 68.4 vs. 24.4%). SGA_L+W children had an intermediate pattern and experienced most gestational hypertension (p = 0.01). At birth, SGA_L+W+HC children were shorter than SGA_L or SGA_L+W (–4.12 vs. –2.67 and –3.72 SDS, p ≤ 0.001). During the first 3 years of life, SGA_L+W+HC children exhibited an increased growth in height (0.98 SDS) and HC (1.28 SDS) than SGA_L (height, –0.06 SDS; HC, –0.30 SDS) and SGA_L+W (height, 0.62 SDS; HC, –0.31 SDS). However, HC SDS remained smaller for SGA_L+W+HC than the other groups at age 3. The groups did not differ in growth response during GH treatment. SGA_L children tended to have shorter parents and target height than SGA_L+W+HC children. Conclusions: Our study shows that subclassification of short SGA children might be a useful method for investigating SGA children as the subgroups revealed a different gestation, delivery and postnatal growth pattern. Response to GH treatment was not different between the groups.

show abstract

Body proportions during 6 years of GH treatment in children with short stature born small for gestational age participating in a randomised, double‐blind, dose–response trial*

Cited by 41 publications

References 26 publications

Reported shoes size during GH therapy: is foot overgrowth a myth or reality?

Reported shoes size during GH therapy: is foot overgrowth a myth or reality?

IGF-I and IGF Binding Protein-3 Generation Tests and Response to Growth Hormone in Children with Silver-Russell Syndrome

Subclassification of Small for Gestational Age Children with Persistent Short Stature: Growth Patterns and Response to GH Treatment

Contact Info

Product

Resources

About